Inflammation and Prostate Cancer: Friends or Foe?

Overview

Journal Inflamm Res

Specialties Allergy & Immunology
Pathology

Date 2015 Mar 20

PMID 25788425

Citations 37

Authors

Gianluigi Taverna

Elisa Pedretti

Giuseppe Di Caro

Elena Monica Borroni

Federica Marchesi

Fabio Grizzi

Affiliations

Soon will be listed here.

Abstract

Introduction: Prostate cancer is the most common non-cutaneous malignancy diagnosed in men. Moving from histological observations since a long time, it has been recognized that innate and adaptive immunity actively participates in the pathogenesis, surveillance, and progression of prostate cancer.

Materials And Methods: A PubMed and Web of Science databases search was performed for studies providing evidence on the roles of the innate and adaptive immunity during the development and progression of prostate cancer.

Conclusions: There are growing evidences that chronic inflammation is involved in the regulation of cellular events in prostate carcinogenesis, including disruption of the immune response and regulation of the tumor microenvironment. This review discusses the role played by the innate and adaptive immune system in the local progression of prostate cancer, and the prognostic information that we can currently understand and exploit.

Citing Articles

Associations between inflammatory burden index, prostate cancer, and mortality among middle-aged and elderly individuals.

Deng J, Hua J, Zeng T, Que H, Zhang Q, Li Q World J Urol. 2024; 42(1):538.

PMID: 39325178 DOI: 10.1007/s00345-024-05241-5.

The Potential Preventive and Therapeutic Roles of NSAIDs in Prostate Cancer.

Maghsoudi H, Sheikhnia F, Sitarek P, Hajmalek N, Hassani S, Rashidi V Cancers (Basel). 2023; 15(22).

PMID: 38001694 PMC: 10670652. DOI: 10.3390/cancers15225435.

Differential Effect of Non-Steroidal Anti-Inflammatory Drugs Aspirin and Naproxen against (Fusion)-Driven and Non-Fusion-Driven Prostate Cancer.

Raina K, Kandhari K, Kant R, Prasad R, Mishra N, Maurya A Cancers (Basel). 2023; 15(20).

PMID: 37894421 PMC: 10605633. DOI: 10.3390/cancers15205054.

TREM2 as an independent predictor of poor prognosis promotes the migration via the PI3K/AKT axis in prostate cancer.

Gao H, Yang Z, Sun H, Zhang Y, Wang Z, Liu W Am J Transl Res. 2023; 15(2):779-798.

PMID: 36915769 PMC: 10006782.

Inflammation and Prostate Cancer: Pathological Analysis from Pros-IT CNR 2.

Sessa F, Nicoletti R, De Nunzio C, Porreca A, Magrini S, Mirone V Cancers (Basel). 2023; 15(3).

PMID: 36765589 PMC: 9913270. DOI: 10.3390/cancers15030630.

References

Balkwill F . The chemokine system and cancer. J Pathol. 2011; 226(2):148-57. DOI: 10.1002/path.3029. View

Zlotnik A, Burkhardt A, Homey B . Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011; 11(9):597-606. DOI: 10.1038/nri3049. View

Allavena P, Germano G, Marchesi F, Mantovani A . Chemokines in cancer related inflammation. Exp Cell Res. 2010; 317(5):664-73. DOI: 10.1016/j.yexcr.2010.11.013. View

Biswas S, Mantovani A . Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010; 11(10):889-96. DOI: 10.1038/ni.1937. View

Peng C, Zhou K, An S, Yang J . The effect of CCL19/CCR7 on the proliferation and migration of cell in prostate cancer. Tumour Biol. 2014; 36(1):329-35. DOI: 10.1007/s13277-014-2642-1. View

Izumi K, Fang L, Mizokami A, Namiki M, Li L, Lin W . Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med. 2013; 5(9):1383-401. PMC: 3799493. DOI: 10.1002/emmm.201202367. View

Presti Jr J . Prostate biopsy strategies. Nat Clin Pract Urol. 2007; 4(9):505-11. DOI: 10.1038/ncpuro0887. View

Gurel B, Lucia M, Thompson Jr I, Goodman P, Tangen C, Kristal A . Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2014; 23(5):847-56. PMC: 4012292. DOI: 10.1158/1055-9965.EPI-13-1126. View

Maxwell P, Neisen J, Messenger J, Waugh D . Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. Oncotarget. 2014; 5(13):4895-908. PMC: 4148108. DOI: 10.18632/oncotarget.2052. View

10.

Kryvenko O, Jankowski M, Chitale D, Tang D, Rundle A, Trudeau S . Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. Mod Pathol. 2012; 25(7):1023-32. PMC: 3589982. DOI: 10.1038/modpathol.2012.51. View

11.

Egevad L . Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation. Anal Quant Cytol Histol. 2008; 30(4):190-8. View

12.

Franco O, Hayward S . Targeting the tumor stroma as a novel therapeutic approach for prostate cancer. Adv Pharmacol. 2012; 65:267-313. DOI: 10.1016/B978-0-12-397927-8.00009-9. View

13.

Velonas V, Woo H, Dos Remedios C, Assinder S . Current status of biomarkers for prostate cancer. Int J Mol Sci. 2013; 14(6):11034-60. PMC: 3709717. DOI: 10.3390/ijms140611034. View

14.

Jaillon S, Galdiero M, Del Prete D, Cassatella M, Garlanda C, Mantovani A . Neutrophils in innate and adaptive immunity. Semin Immunopathol. 2013; 35(4):377-94. DOI: 10.1007/s00281-013-0374-8. View

15.

Zhang J, Lu Y, Pienta K . Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst. 2010; 102(8):522-8. PMC: 2857800. DOI: 10.1093/jnci/djq044. View

16.

Gutkin D, Shurin M . Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol Immunother. 2013; 63(1):45-57. PMC: 4018188. DOI: 10.1007/s00262-013-1480-0. View

17.

Yuan H, Hsiao Y, Zhang Y, Wang J, Yin C, Shen R . Destructive impact of T-lymphocytes, NK and Mast cells on basal cell layers: implications for tumor invasion. BMC Cancer. 2013; 13:258. PMC: 3722065. DOI: 10.1186/1471-2407-13-258. View

18.

Scattoni V, Maccagnano C, Capitanio U, Gallina A, Briganti A, Montorsi F . Random biopsy: when, how many and where to take the cores?. World J Urol. 2014; 32(4):859-69. DOI: 10.1007/s00345-014-1335-0. View

19.

Demichelis F, Stanford J . Genetic predisposition to prostate cancer: Update and future perspectives. Urol Oncol. 2014; 33(2):75-84. DOI: 10.1016/j.urolonc.2014.04.021. View

20.

Lanciotti M, Masieri L, Raspollini M, Minervini A, Mari A, Comito G . The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. Biomed Res Int. 2014; 2014:486798. PMC: 3967497. DOI: 10.1155/2014/486798. View